SCHEMBL567188

SCHEMBL567188

CCCCNC1CCN(S(=O)(=O)c2ccc3cnccc3c2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 1/20 0.43
ROCK2 O75116 5/20 0.41
ROCK1 Q13464 5/20 0.41
JAK2 O60674 2/20 0.41
JAK3 P52333 1/20 0.41
LMNA P02545 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
IKBKB O14920 3/20 0.40
AKR1C3 P42330 1/20 0.40
AKR1C1 Q04828 1/20 0.40
CHUK O15111 2/20 0.39
PKM P14618 1/20 0.39
RAB9A P51151 1/20 0.38
TPSAB1 Q15661 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL567187 1.00 ADRB3 (0.43) ADRB3ROCK2ROCK1JAK2JAK3
Hydrochloric Acid SCHEMBL567427 0.99 ADRB3 (0.42) ADRB3ROCK2ROCK1JAK2JAK3
Hydrochloric Acid SCHEMBL567426 0.99 ADRB3 (0.42) ADRB3ROCK2ROCK1JAK2JAK3
SCHEMBL566183 0.84 LMNA (0.46) ROCK2ROCK1JAK2JAK3LMNA
SCHEMBL566184 0.84 LMNA (0.46) ROCK2ROCK1JAK2JAK3LMNA
Hydrochloric Acid SCHEMBL567692 0.83 LMNA (0.45) ROCK2ROCK1JAK2JAK3LMNA
Hydrochloric Acid SCHEMBL567691 0.83 LMNA (0.45) ROCK2ROCK1JAK2JAK3LMNA
SCHEMBL10135620 0.76 ROCK2 (0.46) ROCK2ROCK1
SCHEMBL566197 0.76 AKR1C3 (0.50) ROCK2ROCK1JAK2JAK3LMNA
SCHEMBL567669 0.76 AKR1C3 (0.47) ROCK2ROCK1JAK2JAK3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2444395-B1 SUBSTITUTED ISOQUINOLINE DERIVATIVE WESTERN THERAPEUTICS INST INC D (JP) 2016-01-06 EP claimed
US-8951997-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2015-02-10 US claimed
EP-2444395-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. Western Therapeutics Institute, Inc. (JP) 2012-04-25 EP claimed
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) 2012-02-09 US claimed
EP-2444395-B1 SUBSTITUTED ISOQUINOLINE DERIVATIVE WESTERN THERAPEUTICS INST INC D (JP) 2016-01-06 EP disclosed
US-8951997-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2015-02-10 US disclosed
EP-2444395-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. Western Therapeutics Institute, Inc. (JP) 2012-04-25 EP disclosed
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE SULT1A1, SULT1E1, SULT2A1 ADRB3 1801/4885ROCK2 1689/4885ROCK1 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.